Programmed cell death-1 (PD-1) is a protein expressed on T cells, B cells, natural killer cells, activated monocytes, and dendritic cells that helps regulate the body’s immune response.1,2 PD-1 is not expressed on resting T cells, and its expression is induced when T cells are activated.2 Known as a “checkpoint protein,” PD-1 binds to its ligands, PD-L1 and PD-L2, which are expressed on a number of cells, including normal and malignant cells to deactivate the T cell, reduce cytokine production, and reduce proliferation of T cells.1,3 This balance is critical to prevent T cells from attacking normal cells in the body.3

Cancer cells exploit this pathway by over-expressing PD-L1 to evade the body’s immune response. PD-L1 is highly expressed on multiple types of cancer cells, including both solid and hematologic malignancies.1 Both PD-1 and PD-L1 are established targets for anticancer therapy.3

Learn more about modality targeting PD-1:
monoclonal antibodies.

Search our clinical trials.

Download additional information from our resources section.


1. Chen DS, Irving BA, Hodi FS. Molecular pathways: next generation immunotherapy—inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18(24):6580-6587.2. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704. 3. American Cancer Society. Immune checkpoint inhibitors to treat cancer. https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/immune-checkpoint-inhibitors.html. Accessed 4/19/2019.